Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic synd...
Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes
About this item
Full title
Author / Creator
Publisher
United States: Centers for Medicare & Medicaid Services
Journal title
Language
English
Formats
Publication information
Publisher
United States: Centers for Medicare & Medicaid Services
Subjects
More information
Scope and Contents
Contents
Erythropoiesis-stimulating agents (ESAs) are widely used to treat anemia associated with myelodysplastic syndromes (MDS) as an off-label indication. In early 2007, the U.S. Food and Drug Administration (FDA) released safety alerts and mandated label changes, and the Centers for Medicare & Medicaid Services (CMS) implemented a National Coverage Dete...
Alternative Titles
Full title
Effect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4254334
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4254334
Other Identifiers
ISSN
2159-0354
E-ISSN
2159-0354
DOI
10.5600/mmrr.004.04.a02
